Syndax Pharmaceuticals Inc financial data

Symbol
SNDX on Nasdaq
Location
730 Third Avenue, 9 Th Floor, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 566 % -42%
Debt-to-equity 132 % +1166%
Return On Equity -130 % -127%
Return On Assets -56.1 % -7.96%
Operating Margin -434 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 86.1M shares +1.23%
Common Stock, Shares, Outstanding 86.1M shares +1.21%
Entity Public Float 1.7B USD
Common Stock, Value, Issued 9K USD 0%
Weighted Average Number of Shares Outstanding, Basic 86.3M shares +1.25%
Weighted Average Number of Shares Outstanding, Diluted 86.3M shares +1.25%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 78.2M USD +985%
Research and Development Expense 260M USD +30.6%
General and Administrative Expense 43.8M USD +50.7%
Operating Income (Loss) -339M USD -17.7%
Nonoperating Income (Expense) 4.06M USD -83%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -335M USD -26.9%
Earnings Per Share, Basic -3 USD/shares -14.1%
Earnings Per Share, Diluted -3 USD/shares -14.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 109M USD +3.07%
Accounts Receivable, after Allowance for Credit Loss, Current 7.6M USD
Inventory, Net 17.7M USD
Other Assets, Current 3.51M USD
Assets, Current 532M USD +19.2%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 1.63M USD +62.9%
Other Assets, Noncurrent 0 USD -100%
Assets 596M USD +25%
Accounts Payable, Current 17.4M USD +50%
Employee-related Liabilities, Current 14.5M USD +86.5%
Liabilities, Current 113M USD +166%
Operating Lease, Liability, Noncurrent 1.58M USD +173%
Liabilities 439M USD +930%
Retained Earnings (Accumulated Deficit) -1.38B USD -32.1%
Stockholders' Equity Attributable to Parent 157M USD -63.8%
Liabilities and Equity 596M USD +25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -95.2M USD -13.9%
Net Cash Provided by (Used in) Financing Activities 930K USD -57.1%
Net Cash Provided by (Used in) Investing Activities 94.1M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 86.1M shares +1.21%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -90K USD +100%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 259M USD +25.6%
Deferred Tax Assets, Gross 259M USD +25.6%
Operating Lease, Liability 2.05M USD +27%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -319M USD -53%
Lessee, Operating Lease, Liability, to be Paid 2.45M USD +35.8%
Property, Plant and Equipment, Gross 419K USD 0%
Operating Lease, Liability, Current 344K USD -64.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 656K USD +8.25%
Lessee, Operating Lease, Liability, to be Paid, Year One 657K USD -45.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 399K USD +111%
Lessee, Operating Lease, Liability, to be Paid, Year Three 675K USD
Deferred Tax Assets, Operating Loss Carryforwards 43.4M USD +32.8%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 143K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 48.4M USD +36.6%
Interest Expense 233K USD -87.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%